Interesting: Brighton Biotech, Inc. Acquires Exclusive Global License For Development, Commercialization Of Vaccines For MERS, SARS Princeton-based international specialty pharma company partners with Baylor College of Medicine. By Becky Taylor, Neighbor Oct 20, 2015 1:27 pm ET
The Baylor and BBI joint efforts are developing prototype subunit vaccines comprised of the SARS and MERS CoV spike proteins, which are the minimal receptor-binding domains, required for binding to the functional viral receptors in humans, Petrin said. He noted that the latest studies in mice with an optimized vaccine/adjuvant formulation have shown 100 percent efficacy with no detectable lung immunopathology, unlike prior attempts at vaccines with toxicity exceeding the risk of the disease itself.
Market Data 
Markets 
AI
